Analysis of a structural polymorphism in the 5-HT2A receptor and clinical response to clozapine.
Clozapine is an atypical antipsychotic with affinity for a broad range of receptors, including serotonin (5-HT) and dopamine receptors. It is successful in treating about 60% of patients refractory to other antipsychotic drugs. Since genetic variation in clozapine's neurotransmitter receptor targets may affect clinical response through altering drug binding or receptor expression, we have studied a His452Tyr polymorphism in the 5-HT2A receptor (HTR2A) in a sample of 153 schizophrenic patients undergoing clozapine treatment and 178 normal controls. An association was found between the allele Tyr452 and poor clinical response.
Arranz
M J
MJ
Department of Psychological Medicine, Institute of Psychiatry, Denmark Hill, London, UK. marranzc@hgmp.mrc.ac.uk
Collier
D A
DA
Munro
J
J
Sham
P
P
Kirov
G
G
Sodhi
M
M
Roberts
G
G
Price
J
J
Kerwin
R W
RW
D000483:Alleles; D014150:Antipsychotic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D003024:Clozapine / Q000494:pharmacology* / Q000627:therapeutic use; D004247:DNA / Q000032:analysis; D005838:Genotype; D006801:Humans; D016133:Polymerase Chain Reaction; D011110:Polymorphism, Genetic; D011569:Psychiatric Status Rating Scales; D011985:Receptors, Serotonin / Q000235:genetics*; D012559:Schizophrenia / Q000188:drug therapy* / Q000235:genetics*
D014150:Antipsychotic Agents; D011985:Receptors, Serotonin; D004247:DNA; D003024:Clozapine